Current Report Filing (8-k)
January 18 2022 - 04:32PM
Edgar (US Regulatory)
0001175151 false 0001175151 2022-01-18
2022-01-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR
15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
January 18, 2022
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36792 |
|
98-0373793 |
(State or other
jurisdiction of
incorporation) |
|
(Commission File
Number) |
|
(I.R.S. Employer
Identification No.) |
|
7 Deer Park Drive,
Suite K,
Monmouth Junction,
New Jersey
|
08852 |
| (Address of principal
executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: (732)
329-8885
|
Not Applicable
|
| (Former name or
former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
| |
¨ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
|
common stock, $0.001 par value |
CTSO |
The
Nasdaq Stock Market LLC (Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 2.02 |
Results of Operations and Financial
Condition. |
On January 18, 2022, CytoSorbents Corporation, a Delaware
corporation (the “Company”), issued a press release and stockholder
letter (the “Release”) and announced certain preliminary financial
results for the quarter and fiscal year ended December 31, 2021. A
copy of the Release is furnished herewith as Exhibit 99.1.*
* The information in Item 2.02 of this Form 8-K shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act
of 1934 (the “Exchange Act”) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
As further described in the Release, the Company has decided to
voluntarily end the REFRESH 2-AKI study, which remains blinded, and
the CYTATION trial. These decisions were made strictly for business
reasons to ensure focus on the vital U.S. STAR-T and STAR-D
clinical programs and not as a result of any safety issues.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Dated: January 18,
2022 |
CYTOSORBENTS
CORPORATION |
| |
|
|
| |
By: |
/s/ Dr. Phillip P. Chan |
| |
Name: |
Dr. Phillip P. Chan |
| |
Title: |
Chief Executive
Officer |
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Apr 2022 to May 2022
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From May 2021 to May 2022
